The CXO sector continued to be strong, with steady growth in corporate performance in this area

"Pharmaceutical Network Industry Dynamics" CXO company is known as the pharmaceutical research and development industry", with the accelerated development of innovative pharmaceutical industry, as well as pharmaceutical companies continue to high investment in research and development, this year, the CXO industry as a whole has maintained a high degree of prosperity, performance achieved steady growth.
CXO, which recently disclosed its semi-annual results, reported strong results in the first half of the year.
2020 mid-year report released on August 26th showed that the company achieved revenue of 459 million yuan in the first half of this year, up 58.17 percent year-on-year, and net profit of 0.87 billion yuan, up 26.08 percent year-on-year.
quarter, the company's Q2 revenue, attributable net profit and non-attributed net profit growth rate of 108.46 percent, 65.35 percent and 66.78 percent, respectively, the performance has a clear accelerated growth trend.
that Q2 quarter, benefiting from the company's kilogram orders and technical services revenue growth, performance fully restored to a high-growth state.
public information shows that Pharmaceutical Stone Technology is mainly a global supplier of innovative chemical products and services in the field of drug research and development, the main business includes the design, synthesis and sale of pharmaceutical molecular blocks, process development of key intermediates, pilot, commercial production and sales, pharmaceutical molecular blocks downstream related raw materials process research and development services.
From the company's business revenue segment, the company's business revenue above the kg class in the first half of this year was 349 million yuan, up 76.8% YoY;
, the proportion of business revenue above the kg class reached more than 70%, and achieved high-speed growth.
company disclosed the report shows that in the first half of this year, the company's key customer projects cooperation growth is obvious, the completion of more than 200 different series of molecular block production business, mainly due to the second quarter of overseas orders to domestic transfer.
addition to the company's "inventory items" smooth progress, the early order items have made some progress.
growth in business income below the kg level has slowed, possibly due to reduced overseas projects and capacity constraints.
Kanglong into the first half of the results are very bright.
first half of this year, the company achieved revenue of RMB2,193 million, up 34.01% YoY, and net profit of RMB479 million, up 196.89 percent YoY.
company's profits to achieve high growth, the overall profitability further improved.
public information shows that Kanglonghua is a process-wide integrated pharmaceutical research and development service platform, committed to helping customers accelerate drug innovation, but also China's second largest pharmaceutical research and development service platform and one of the world's three major drug discovery service providers.
In terms of the company's business situation in the three major sectors in 2020, its laboratory services, CMC services and clinical research services have all returned to high growth: laboratory services revenue of 1.434 billion yuan, up 35.28% YoY;
Q2, its CMC services business segment returned to high growth, while the clinical research services segment Q2 was affected by overseas clinical business, with slower performance growth relative to the other two sectors.
In the first half of 2020, Kanglonghua introduced more than 190 new customers, of which more than 90% came from the company's large, diversified and loyal repeat customers, including the world's top 20 pharmaceutical companies, and conducted 28 clinical trials of new research drugs for domestic pharmaceutical and biotechnology companies, including 20 simultaneously declared projects in many countries (including China, the United States and Europe).
company is expected to rely on high-quality customer resources and its own research and development advantages, and steadily improve the level of profitability.